Transcranial Focused Ultrasound and SHP2 Pathway: A Mechanistic Study in Post-Stroke Neuroinflammation

Study Background and Research Question

Acute ischemic stroke remains a leading cause of neurological disability worldwide. The standard of care, intravenous thrombolysis with recombinant tissue-type plasminogen activator (r-tPA), is limited by a narrow therapeutic window and strict eligibility criteria, meaning that the majority of stroke patients do not benefit from this intervention. As a result, there is substantial interest in adjunctive or alternative therapies capable of mitigating post-ischemic neuroinflammation—a process that exacerbates neuronal injury and impedes recovery. Microglia-driven neuroinflammation, especially via activation of the NLRP3 inflammasome, is recognized as a key pathological driver of post-stroke damage. Non-invasive neuromodulation techniques, including transcranial focused ultrasound stimulation (tFUS), have shown promise in animal models, but their molecular mechanisms of action remain incompletely understood.

Key Innovation from the Reference Study

The referenced study (International Immunopharmacology, 2025) provides mechanistic clarity by demonstrating that tFUS exerts neuroprotective effects through modulation of the Nespas/miR-383-3p/SHP2 signaling axis in a rat model of ischemic stroke. Notably, the work identifies SHP2 (src homology 2 domain-containing tyrosine phosphatase-2) as a crucial mediator in suppressing NLRP3 inflammasome activation within microglia. The study positions SHP2 as both a readout and a potential intervention point for future research into neuroinflammation following acute ischemic injury.

Methods and Experimental Design Insights

The research employed a transient middle cerebral artery occlusion (MCAO) model in rats to mimic ischemic stroke. Low-intensity tFUS was applied to the affected hemisphere 24 hours post-MCAO for seven consecutive days. To assess the impact on neuroinflammation, the investigators performed a series of neurobehavioral assessments, infarct volume measurements, and molecular analyses—including western blotting, immunofluorescence, and quantitative real-time PCR—on brain tissues. Complementary in vitro experiments utilized BV2 microglial cells subjected to oxygen-glucose deprivation/reperfusion (OGD/R) to model ischemic insult at the cellular level. RNA sequencing and transient transfection approaches were used to dissect the molecular pathway, particularly focusing on the roles of Nespas (a long noncoding RNA), miR-383-3p, and SHP2 in the regulation of NLRP3 inflammasome activation.

Protocol Parameters

• MCAO induction: Transient occlusion of the middle cerebral artery in rats to model focal cerebral ischemia.
• tFUS application: Low-intensity stimulation commenced 24 hours after MCAO, administered daily for 7 days to the ischemic hemisphere.
• Neurobehavioral assessment: Conducted post-treatment to evaluate functional recovery.
• Molecular endpoints: NLRP3 inflammasome activation (protein and mRNA levels), Nespas and miR-383-3p expression, SHP2 abundance, and downstream inflammatory cytokines.
• In vitro OGD/R model: BV2 microglial cells subjected to oxygen-glucose deprivation and reperfusion, with or without genetic modulation of Nespas or SHP2.

Core Findings and Why They Matter

The principal findings are as follows:

• tFUS improved neurological function in MCAO rats, as evidenced by better neurobehavioral scores and reduced infarct size compared to controls.
• NLRP3 inflammasome activation was significantly suppressed in tFUS-treated animals and corresponding cell models, correlating with reduced production of pro-inflammatory cytokines.
• Nespas expression was upregulated following tFUS, while silencing Nespas reversed the neuroprotective and anti-inflammatory effects of tFUS, leading to enhanced NLRP3 activation and worsened outcomes.
• Nespas positively regulates SHP2 via miR-383-3p, and inhibition of SHP2 intensified NLRP3 inflammasome activation, supporting a model in which the Nespas/miR-383-3p/SHP2 axis serves as a molecular brake on microglial inflammation.
• Mechanistically, tFUS-induced upregulation of Nespas leads to increased SHP2 activity, which in turn suppresses the pathological activation of the NLRP3 inflammasome, thereby attenuating neuroinflammation and supporting functional recovery.

These data collectively provide a mechanistic rationale for the use of tFUS as a non-invasive intervention in ischemic brain injury, and highlight the Nespas/miR-383-3p/SHP2 pathway as an actionable target for future pharmacological or genetic approaches.

Comparison with Existing Internal Articles

Several recent articles expand on the mechanistic and translational implications of SHP2 modulation in neuroinflammation and related disease states. For instance, "tFUS Attenuates Stroke-Induced Neuroinflammation via SHP2 Pathway" and "tFUS Alleviates Post-Stroke Neuroinflammation via Nespas/miR-383-3p/Shp2 Axis" both reinforce the finding that SHP2 is a central regulatory node in microglial responses to ischemic injury. These articles elaborate on how noninvasive neuromodulation can modulate molecular networks, converging on SHP2 as a consistent effector. Furthermore, detailed reviews such as "NSC 87877: Illuminating Shp2 Pathways in Neuroinflammation and Cancer" and "NSC 87877: Selective Shp2 Inhibition for Neuroinflammation & Pain" provide complementary evidence on the applications of SHP2 inhibitors, including their utility in dissecting the molecular mechanisms of neuroinflammatory signaling, pain modulation, and oncogenic processes. These internal resources consistently underscore SHP2’s pivotal role and its value as a research target, while the present reference study uniquely demonstrates a non-pharmacological route to SHP2 pathway activation via tFUS.

Limitations and Transferability

While the study offers compelling evidence for tFUS-mediated neuroprotection via the Nespas/miR-383-3p/SHP2 axis in a preclinical rat model, certain limitations should be considered. The findings are specific to the MCAO model and low-intensity tFUS parameters; thus, transferability to other ischemic models or to human patients remains to be rigorously established. Additionally, while genetic silencing and pharmacological inhibition of SHP2 were used to probe mechanism, off-target effects and the complex interplay of upstream and downstream effectors in vivo may confound direct translation. Future studies should address long-term outcomes, sex differences, and potential side effects associated with chronic neuromodulation or SHP2 pathway manipulation.

Research Support Resources

For researchers interested in further exploring the SHP2-mediated regulation of neuroinflammation, chemical tools such as NSC 87877 (SKU A4544) are available. NSC 87877 is a potent and selective inhibitor of SHP2 and SHP1, and has been characterized as a Shp2 inhibitor with high selectivity over related phosphatases. Its use can help delineate the contribution of SHP2 to neuroinflammatory processes, as demonstrated in studies of EGF-induced Erk1/2 activation, leukemic cell line cytotoxicity, and inflammatory pain models (internal review). For experimental workflows investigating the SHP2/NLRP3 axis in microglia or related cell types, NSC 87877 offers a practical research compound to complement genetic approaches. For detailed chemical and handling information, consult the APExBIO product page.